Member Info for howdlep

A very nice delayed premium buy of 582k @ 3,42p. Now they want twice the size. No wonder MM's can't find sellers. Sooner or later the buy and sell price will have to go up.

MM now bidding 3.35p for 1.2m

As a MM is currently bidding 3.35p for 750,000

Very interesting

A nice little flurry of buys gone through and we have two-way liquidity. Good to see.

Exactly right. Chartists can only ever predict the next technical target, as in the long run, news will determine future direction. We have so much to look forward to.

Zak Mir notes the bounce, after strong news, from neckline resistance at circa 3.25p. Now targets 4.75p, maybe even as high as 6p by the end of next month. This while support holds at 3.2p, the former resistance:-

https://zakstraderscafe.com/weekend-bulletin-board-heroes-august-20/7548/

No this is additional.

"The Company submitted its second Orphan Drug Designation request to the FDA for treating pediatric brain tumors with GaM. A decision is expected by early Q3".

Comment: Shares of IQ-AI spiked in March towards 5p, and arguably deserve to do the same now in the wake of the latest two pre-clinical studies. Hopefully we are in run up to the FDA green light, given the seriousness of pediatric brain tumours.

https://zakstraderscafe.com/rns-hotlist-june-27-atome-cadence-creo-galileo-iq-ai-panther-seed/7229/

Good to see IB tweeting about this partnership, as highlighted by maximillion69

Https://twitter.com/IQAI_IB/status/1667225000326336517

I wonder whether IB will acquire Prism at some point in the future, as the benefits are quite clear in this article:-

Https://axisimagingnews.com/imaging-news/company-news/imaging-biometrics-prism-clinical-imaging-link-up

Note, the Michael Schmainda link between both companies, as highlighted on IB's website:-

Https://iqai.ltd/#eluid6a7a4c28

"Michael's career began with 3M Company, a company renowned for bringing new products to market, where he held leadership roles across multiple industries including the life science sector. Prior to IB, Michael was a foundational member of Prism Clinical Imaging, secured the initial investment for the company, and served as president and COO."

I couldn't agree more re the multiple valuation and I think it will be realised in our companies financial year.

So much newslow pending, not least the clincial trials.

Now is the time for a predator to make its move, with our cap market being so low. But will it come from big pharma or big tech?

I suspect an offer from one will generate interest/offers from others.

Now is the time to be accumulating positions in readiness.

I had a problem this morning with the recommendation display of messages and the ability to click URL's containd within any message. The former now seems ok after I changed password and re signed in. However, the latter is still a problem.

Anyone else experiencing problems?

This was issued just before the Finals, so a new update will be out in due course. However, it doesn't help with PR when the analyst misses off #IQAI from her tweets, as the report often goes unnoticed unless searching with $IQAIF. This is why I retweet company tweets with both #IQAI and $IQAIF.

https://crystalequityresearch.com/wp-content/uploads/2023/04/IQAI-IQAIF-Update-Report-April-27-2023.pdf

Exciting indeed, but this should have been worthy of an RNS today!!

Exciting! @IQAI_IB's quantitative neuro solutions included in TR's newly launched Neuro Suite!

ConcertAI's TeraRecon Adds the Releases of an AI-Assisted Clinical Suite Solution, Neuro Suite to Provide Comprehensive Solutions for Neurological Disorders

https://twitter.com/IQAI_IB/status/1654555245291110401

Who are TeraRecon?

https://www.terarecon.com/about?locale=en

Hi Tyke68,
The vesting date is the earliest date an option can be exercised.
DS was granted an option to 6,017,500 shares on 1/11/18, with 1/3 (2,005,823) vesting on 1/8/19.
He then exercised 1m @ 2.6p on 13/1/20 which cost him £26k. These can be sold whenever he wants.
The remaining 2/3 vest over the next 36 months, pro rata at the end of EACH month (ending 1/8/22).
He still has not exercised 5,017,500 of those options.
23p relates to the intra day high. I am sure a lot of people regretted not selling and buying back. All depends on your timeframe I guess. In relatoin to DS, these options lapse (expire) on 1/8/28.
I hope that helps.
Regards
Phil

On the 1st November 2018, David Smith was granted options over 6,017,500 shares at 2.6p. 1/3 of those shares vested on 1st November 2019, with the remainder at 1/36 on the last day of each month thereafter.

David exercised 1m shares at 2.6p on 13th January 2020 when the share price was circa 4p. Since then, the share price rose to circa 23p in November 2020. However, David does not seem to have exercise any further options.

So with over 5m shares still to be exercised, David is clearly very confident that the share price is going to rise above 23p in the remaining years, before they lapse on 1st August 2028.

On the 1st November 2018, David Smith was granted options over 6,017,500 shares at 2.6p. 1/3 of those shares vested on 1st November 2019, with the remainder at 1/36 on the last day of each month thereafter.

David exercised 1m shares at 2.6p on 13th January 2020 when the share price was circa 4p. Since then, the share price rose to circa 23p in November 2020. However, David does not seem to have exercise any further options.

So with over 5m shares still to be exercised, David is clearly very confident that the share price is going to rise above 23p in the remaining years, before they lapse on 1st August 2028.

That being the case, how confident should shareholders be now, knowing the share price is currently at circa the exercise price. Quite simply, you now have the same opportunity as David!

Hi Trek,

Thanks for the reply.

You make some very interesting points re what may happen in the future.

TB didn't sell any shares and convert an equivelent value in CLN's. In the finals reported. the total outstanding value of CLN's increased only by the associated interest.

As for the 'concert party' association with famiy & friends re FAB, I stand by my opinion. Perhaps that is something you could confirm with your advisory broker or IQAI's corporate broker, as I would be very interested in their reply?

What is for certain, I think we are entering a news rich period where a share price revaluation will take place. But timing is everything.

Regards
Phil

are the same as per 2022 https://iqai.ltd/wpiqai/wp-content/uploads/2022/05/2022-IQ-AI-AGM-Notice.pdf

If they buy back it will be to cancel shares sold. If they allot new shares it would be for placings, acquisitions or CLN exercise. IMO they will not be cancelling shares sold as it would take TB over 30%, inclusive of concert party FAB shares.

I am happy to be corrected by others.

As shareholders should be aware, the partnership was confirmed via a IQAI tweet on the 20 April (https://twitter.com/IQAI_IB/status/1649173997039353856) and by both companies on their respective Linkedin pages. I all cases, this was via a link to an Auntminnie news release.

Michael Schmainda, CEO of Imaging Biometrics, was the President and COO of Kyron Clinical Imaging between February 2006 and February 2007. Kyron Clinical Imaging became Prism Clinical Imaging in February 2008 https://www.itnonline.com/content/kyron-clinical-imaging-changes-name-prism-clinical-imaging

As IQAI's Investor Relations page states (https://iqai.ltd/#eluid87d71e9b), "Michael's career began with 3M Company, a company renowned for bringing new products to the market, where he held leadership roles across multiple industries including the life science sector. Prior to IB, Michel was a foundational member of Prism Clinical Imaging, secured the initial investment for the company and served as President and COO."

So do we really need an RNS to highlight the longstanding links between the two companies?
I guess if you are a potential shareholder, rather than a longstanding one, that may be appropriate.

just two spread betting rollovers.

MPs are demanding action to make brain tumour research a "critical priority", after a landmark report showed child survival rates have remained unchanged for decades.

https://twitter.com/howdlep/status/1632015598145208322